GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (FRA:9EN) » Definitions » EV-to-FCF

Pharvaris NV (FRA:9EN) EV-to-FCF : -3.96 (As of Apr. 04, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Pharvaris NV EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pharvaris NV's Enterprise Value is €433.45 Mil. Pharvaris NV's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was €-109.39 Mil. Therefore, Pharvaris NV's EV-to-FCF for today is -3.96.

The historical rank and industry rank for Pharvaris NV's EV-to-FCF or its related term are showing as below:

FRA:9EN' s EV-to-FCF Range Over the Past 10 Years
Min: -3.96   Med: 0   Max: 0
Current: -3.96

FRA:9EN's EV-to-FCF is ranked worse than
100% of 440 companies
in the Biotechnology industry
Industry Median: 2.895 vs FRA:9EN: -3.96

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-04), Pharvaris NV's stock price is €13.10. Pharvaris NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-2.601. Therefore, Pharvaris NV's PE Ratio (TTM) for today is At Loss.


Pharvaris NV EV-to-FCF Historical Data

The historical data trend for Pharvaris NV's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharvaris NV EV-to-FCF Chart

Pharvaris NV Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - - -4.76 -2.94 -10.24

Pharvaris NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.15 -10.24 -8.46 -6.01 -5.57

Competitive Comparison of Pharvaris NV's EV-to-FCF

For the Biotechnology subindustry, Pharvaris NV's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharvaris NV's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharvaris NV's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Pharvaris NV's EV-to-FCF falls into.


;
;

Pharvaris NV EV-to-FCF Calculation

Pharvaris NV's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=433.449/-109.391
=-3.96

Pharvaris NV's current Enterprise Value is €433.45 Mil.
Pharvaris NV's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-109.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharvaris NV  (FRA:9EN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Pharvaris NV's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=13.10/-2.601
=At Loss

Pharvaris NV's share price for today is €13.10.
Pharvaris NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.601.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Pharvaris NV EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Pharvaris NV's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharvaris NV Business Description

Traded in Other Exchanges
Address
Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Pharvaris NV Headlines

No Headlines